|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sanyal AJ, Yoon SK and Lencioni R: The
etiology of hepatocellular carcinoma and consequences for
treatment. Oncologist. 15:(Suppl 4). 14–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Asia-Pacific Working Party on Prevention
of Hepatocellular Carcinoma: Prevention of hepatocellular carcinoma
in the Asia-Pacific region: consensus statements. J Gastroenterol
Hepatol. 25:657–663. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu D, Dong L, Liu Y, Wen D, Gao D, Sun H,
Fan J and Wu W: A c-Myc/miR-17-5p feedback loop regulates
metastasis and invasion of hepatocellular carcinoma. Tumour Biol.
37:5039–5047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsieh MY, Lin ZY, Chen SH and Chuang WL:
Risk factors for the leakage of chemotherapeutic agents into
systemic circulation after transcatheter arterial chemoembolization
of hepatocellular carcinoma. Kaohsiung J Med Sci. 27:431–436. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang LY, Fang F, Ou DP, Wu W, Zeng ZJ and
Wu F: Solitary large hepatocellular carcinoma: A specific subtype
of hepatocellular carcinoma with good outcome after hepatic
resection. Ann Surg. 249:118–123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y and Kowdley KV: MicroRNAs in common
human diseases. Genomics Proteomics Bioinformatics. 10:246–253.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wightman B, Ha I and Ruvkun G:
Posttranscriptional regulation of the heterochronic gene lin-14 by
lin-4 mediates temporal pattern formation in C. elegans. Cell.
75:855–862. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kozomara A and Griffiths-Jones S: miRBase:
Integrating microRNA annotation and deep-sequencing data. Nucleic
Acids Res. 39:D152–D157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Hara SP, Mott JL, Splinter PL, Gores GJ
and LaRusso NF: MicroRNAs: Key modulators of posttranscriptional
gene expression. Gastroenterology. 136:17–25. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lujambio A and Lowe SW: The microcosmos of
cancer. Nature. 482:347–355. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iorio MV and Croce CM: microRNA
involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ebert MS and Sharp PA: Roles for microRNAs
in conferring robustness to biological processes. Cell.
149:515–524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang N, Ekanem NR, Sakyi CA and Ray SD:
Hepatocellular carcinoma and microRNA: New perspectives on
therapeutics and diagnostics. Adv Drug Deliv Rev. 81:62–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Romero-Cordoba SL, Salido-Guadarrama I,
Rodriguez-Dorantes M and Hidalgo-Miranda A: miRNA biogenesis:
Biological impact in the development of cancer. Cancer Biol Ther.
15:1444–1455. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lan H, Lu H, Wang X and Jin H: MicroRNAs
as potential biomarkers in cancer: Opportunities and challenges.
Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Petri A, Lindow M and Kauppinen S:
MicroRNA silencing in primates: Towards development of novel
therapeutics. Cancer Res. 69:393–395. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Landi MT, Zhao Y, Rotunno M, Koshiol J,
Liu H, Bergen AW, Rubagotti M, Goldstein AM, Linnoila I, Marincola
FM, et al: MicroRNA expression differentiates histology and
predicts survival of lung cancer. Clin Cancer Res. 16:430–441.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He J, Gu D, Wu X, Reynolds K, Duan X, Yao
C, Wang J, Chen CS, Chen J, Wildman RP, et al: Major causes of
death among men and women in China. N Engl J Med. 353:1124–1134.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen X, Bo L, Lu W, Zhou G and Chen Q:
MicroRNA-148b targets Rho-associated protein kinase 1 to inhibit
cell proliferation, migration and invasion in hepatocellular
carcinoma. Mol Med Rep. 13:477–482. 2016.PubMed/NCBI
|
|
27
|
Chen X, Bo L, Zhao X and Chen Q:
MicroRNA-133a inhibits cell proliferation, colony formation
ability, migration and invasion by targeting matrix
metallopeptidase 9 in hepatocellular carcinoma. Mol Med Rep.
11:3900–3907. 2015.PubMed/NCBI
|
|
28
|
Pang X, Huang K, Zhang Q, Zhang Y and Niu
J: miR-154 targeting ZEB2 in hepatocellular carcinoma functions as
a potential tumor suppressor. Oncol Rep. 34:3272–3279.
2015.PubMed/NCBI
|
|
29
|
Wu ZY, Wang SM, Chen ZH, Huv SX, Huang K,
Huang BJ, Du JL, Huang CM, Peng L, Jian ZX and Zhao G: MiR-204
regulates HMGA2 expression and inhibits cell proliferation in human
thyroid cancer. Cancer Biomark. 15:535–542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu D, Pan H, Zhou Y, Zhang Z, Qu P, Zhou J
and Wang W: Upregulation of microRNA-204 inhibits cell
proliferation, migration and invasion in human renal cell carcinoma
cells by downregulating SOX4. Mol Med Rep. 12:7059–7064.
2015.PubMed/NCBI
|
|
31
|
Wang X, Qiu W, Zhang G, Xu S, Gao Q and
Yang Z: MicroRNA-204 targets JAK2 in breast cancer and induces cell
apoptosis through the STAT3/BCl-2/survivin pathway. Int J Clin Exp
Pathol. 8:5017–5025. 2015.PubMed/NCBI
|
|
32
|
Xia Z, Liu F, Zhang J and Liu L: Decreased
expression of MiRNA-204-5p contributes to glioma progression and
promotes glioma cell growth, migration and invasion. PLoS One.
10:e01323992015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Butrym A, Rybka J, Baczynska D, Tukiendorf
A, Kuliczkowski K and Mazur G: Low expression of microRNA-204
(miR-204) is associated with poor clinical outcome of acute myeloid
leukemia (AML) patients. J Exp Clin Cancer Res. 34:682015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shi Y, Huang J, Zhou J, Liu Y, Fu X, Li Y,
Yin G and Wen J: MicroRNA-204 inhibits proliferation, migration,
invasion and epithelial-mesenchymal transition in osteosarcoma
cells via targeting Sirtuin 1. Oncol Rep. 34:399–406.
2015.PubMed/NCBI
|
|
35
|
Yan H, Wu W, Ge H, Li P and Wang Z:
Up-regulation of miR-204 enhances anoikis sensitivity in epithelial
ovarian cancer cell line via brain-derived neurotrophic factor
pathway in vitro. Int J Gynecol Cancer. 25:944–952. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu L, Wang J, Li X, Ma J, Shi C, Zhu H,
Xi Q, Zhang J, Zhao X and Gu M: MiR-204-5p suppresses cell
proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma.
Biochem Biophys Res Commun. 457:621–626. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li W, Jin X, Zhang Q, Zhang G, Deng X and
Ma L: Decreased expression of miR-204 is associated with poor
prognosis in patients with breast cancer. Int J Clin Exp Pathol.
7:3287–3292. 2014.PubMed/NCBI
|
|
38
|
Mao J, Zhang M, Zhong M, Zhang Y and Lv K:
MicroRNA-204, a direct negative regulator of ezrin gene expression,
inhibits glioma cell migration and invasion. Mol Cell Biochem.
396:117–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wu D, Niu X, Pan H, Zhou Y, Qu P and Zhou
J: MicroRNA-335 is downregulated in bladder cancer and inhibits
cell growth, migration and invasion via targeting ROCK1. Mol Med
Rep. 13:4379–4385. 2016.PubMed/NCBI
|
|
40
|
Bindels S, Mestdagt M, Vandewalle C,
Jacobs N, Volders L, Noël A, van Roy F, Berx G, Foidart JM and
Gilles C: Regulation of vimentin by SIP1 in human epithelial breast
tumor cells. Oncogene. 25:4975–4985. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kurashige J, Kamohara H, Watanabe M,
Hiyoshi Y, Iwatsuki M, Tanaka Y, Kinoshita K, Saito S, Baba Y and
Baba H: MicroRNA-200b regulates cell proliferation, invasion, and
migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg
Oncol. 19:(Suppl 3). S656–S664. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chu PY, Hu FW, Yu CC, Tsai LL, Yu CH, Wu
BC, Chen YW, Huang PI and Lo WL: Epithelial-mesenchymal transition
transcription factor ZEB1/ZEB2 co-expression predicts poor
prognosis and maintains tumor-initiating properties in head and
neck cancer. Oral Oncol. 49:34–41. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Qi S, Song Y, Peng Y, Wang H, Long H, Yu
X, Li Z, Fang L, Wu A, Luo W, et al: ZEB2 mediates multiple
pathways regulating cell proliferation, migration, invasion, and
apoptosis in glioma. PLoS One. 7:e388422012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cai MY, Luo RZ, Chen JW, Pei XQ, Lu JB,
Hou JH and Yun JP: Overexpression of ZEB2 in peritumoral liver
tissue correlates with favorable survival after curative resection
of hepatocellular carcinoma. PLoS One. 7:e328382012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wu Q, Guo R, Lin M, Zhou B and Wang Y:
MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration
and invasion by targeting E-cadherin repressor ZEB2. Gynecol Oncol.
122:149–154. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gemmill RM, Roche J, Potiron VA, Nasarre
P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA and
Drabkin HA: ZEB1-responsive genes in non-small cell lung cancer.
Cancer Lett. 300:66–78. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yang Z, Sun B, Li Y, Zhao X, Zhao X, Gu Q,
An J, Dong X, Liu F and Wang Y: ZEB2 promotes vasculogenic mimicry
by TGF-β1 induced epithelial-to-mesenchymal transition in
hepatocellular carcinoma. Exp Mol Pathol. 98:352–359. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Du Y, Wang L, Wu H, Zhang Y, Wang K and Wu
D: MicroRNA-141 inhibits migration of gastric cancer by targeting
zinc finger E-box-binding homeobox 2. Mol Med Rep. 12:3416–3422.
2015.PubMed/NCBI
|
|
49
|
Zhou J, Xie M, Shi Y, Luo B, Gong G, Li J,
Wang J, Zhao W, Zi Y, Wu X and Wen J: MicroRNA-153 functions as a
tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer
cells. Oncol Rep. 34:111–120. 2015.PubMed/NCBI
|
|
50
|
Chen Z, Tang ZY, He Y, Liu LF, Li DJ and
Chen X: miRNA-205 is a candidate tumor suppressor that targets ZEB2
in renal cell carcinoma. Oncol Res Treat. 37:658–664. 2014.
View Article : Google Scholar : PubMed/NCBI
|
